Arvinas (ARVN)

• Market cap: $1.29B
• 1 day: 4.11%
• 5 days: -1.99%
• 1 month: -25.49%
• 3 months: -24.22%
• 6 months: -24.95%
• Year to date: -54.84%
• 1 year: -54.39%
• 5 years: -56.16%
• 10 years: 16.76%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Employees: 445

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

11% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 64

0% less funds holding

Funds holding: 205 [Q2] → 204 (-1) [Q3]

4% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 28

1.34% less ownership

Funds ownership: 104.79% [Q2] → 103.45% (-1.34%) [Q3]

8% less capital invested

Capital invested by funds: $1.91B [Q2] → $1.75B (-$159M) [Q3]

19% less call options, than puts

Call options by funds: $5.79M | Put options by funds: $7.15M

29% less funds holding in top 10

Funds holding in top 10: 7 [Q2] → 5 (-2) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $40 113% upside
• Avg. target: $68 260% upside
• High target: $88 370% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 102 / 328 met price target	364% upside $87	Buy Reiterated	11 Dec 2024
BMO Capital Etzer Darout 29% 1-year accuracy 12 / 41 met price target	370% upside $88	Outperform Maintained	20 Nov 2024
Stephens & Co. Sudan Loganathan 21% 1-year accuracy 4 / 19 met price target	193% upside $55	Overweight Initiated	18 Nov 2024
Oppenheimer Matthew Biegler 0% 1-year accuracy 0 / 28 met price target	113% upside $40	Outperform Maintained	31 Oct 2024